NCT04465760: Xisomab 3G3 for the Prevention of Catheter-Associated Thrombosis

NCT04465760
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 2
Drug Category: Therapeutic Antibody

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patient must be scheduled to undergo insertion of a PICC line or indwelling central venous catheter as part of planned anticancer therapy per institutional standards
Exclusions: Patients with known brain metastasis
https://ClinicalTrials.gov/show/NCT04465760

Comments are closed.

Up ↑